Ceftobiprole Medocaril Sodium
The sodium salt of the ceftobiprole prodrug is used intravenously for serious bacterial pneumonias including those caused by MRSA and Pseudomonas aeruginosa. As a fifth-generation cephalosporin, it binds to MRSA-specific PBP2a in addition to other penicillin-binding proteins. Renal function should be monitored as dose adjustments are necessary in kidney impairment.
分子量
690.7000 g/mol
LogP
0.40
TPSA
310.00 Ų
リピンスキーの五則
不適合
作用機序
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
2D構造
Cite this structure
Embed this structure
SMILES
Cc1oc(=O)oc1COC(=O)N1CC[C@@H](N2CC/C(=C\C3=C(C(=O)[O-])N4C(=O)[C@@H](NC(=O)/C(=N/O)c5nsc(N)n5)[C@H]4SC3)C2=O)C1.[Na+]
InChI
InChI=1S/C26H26N8O11S2.Na/c1-10-14(45-26(41)44-10)8-43-25(40)32-4-3-13(7-32)33-5-2-11(20(33)36)6-12-9-46-22-16(21(37)34(22)17(12)23(38)39)28-19(35)15(30-42)18-29-24(27)47-31-18;/h6,13,16,22,42H,2-5,7-9H2,1H3,(H,28,35)(H,38,39)(H2,27,29,31);/q;+1/p-1/b11-6+,30-15+;/t13-,16-,22-;/m1./s1
Molecular Formula
C26H26N8O11S2
HBD / HBA
4 / 17
回転可能結合数
9
重原子数
47
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
The sodium salt of the ceftobiprole prodrug is used intravenously for serious bacterial pneumonias including those caused by MRSA and Pseudomonas aeruginosa. As a fifth-generation cephalosporin, it binds to MRSA-specific PBP2a in addition to other penicillin-binding proteins. Renal function should be monitored as dose adjustments are necessary in kidney impairment.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Ceftobiprole Medocaril Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297101. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 135413544. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ceftobiprole-medocaril-sodium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ceftobiprole-medocaril-sodium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ceftobiprole-medocaril-sodium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ceftobiprole-medocaril-sodium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ceftobiprole-medocaril-sodium"></drugfyi-drug>